RESUMO
Large-scale restoration programmes in the tropics require large volumes of high quality, genetically diverse and locally adapted seeds from a large number of species. However, scarcity of native seeds is a critical restriction to achieve restoration targets. In this paper, we analyse three successful community-based networks that supply native seeds and seedlings for Brazilian Amazon and Cerrado restoration projects. In addition, we propose directions to promote local participation, legal, technical and commercialisation issues for up-scaling the market of native seeds for restoration with high quality and social justice. We argue that effective community-based restoration arrangements should follow some principles: (i) seed production must be based on real market demand; (ii) non-governmental and governmental organisations have a key role in supporting local organisation, legal requirements and selling processes; (iii) local ecological knowledge and labour should be valued, enabling local communities to promote large-scale seed production; (iv) applied research can help develop appropriate techniques and solve technical issues. The case studies from Brazil and principles presented here can be useful for the up-scaling restoration ecology efforts in many other parts of the world and especially in tropical countries where improving rural community income is a strategy for biodiversity conservation and restoration.
Assuntos
Sementes , Biodiversidade , Brasil , Conservação dos Recursos Naturais , EcologiaRESUMO
The new alleles, HLA-B*40:125 and HLA-B*40:129, present a mismatch at codon 103.1 (G â C) and three mismatches at codons 9.1 (C â T), 11.1 (T â G) and 12.1 (G â A).
Assuntos
Antígenos HLA-B/genética , Alelos , Sequência de Bases , Transplante de Medula Óssea/etnologia , Transplante de Medula Óssea/imunologia , Brasil , Clonagem Molecular , Etnicidade , Éxons , Feminino , Loci Gênicos , Antígenos HLA-B/imunologia , Teste de Histocompatibilidade , Humanos , Masculino , Dados de Sequência Molecular , Nucleotídeos/química , Nucleotídeos/genética , Mutação Puntual , Reação em Cadeia da Polimerase , Polimorfismo Genético , Sistema de Registros , Análise de Sequência de DNAAssuntos
Neoplasias Encefálicas/patologia , Dura-Máter/patologia , Linfoma de Zona Marginal Tipo Células B/patologia , Neoplasias Encefálicas/terapia , Terapia Combinada , Diabetes Mellitus , Diagnóstico Diferencial , Feminino , Humanos , Hipertensão/complicações , Linfoma de Zona Marginal Tipo Células B/terapia , Imageamento por Ressonância Magnética , Meningioma/patologia , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Tomografia Computadorizada por Raios XAssuntos
Hepatopatias Parasitárias/tratamento farmacológico , Contagem de Ovos de Parasitas/métodos , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Adolescente , Adulto , Animais , Disponibilidade Biológica , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Praziquantel/farmacocinética , Praziquantel/farmacologia , Distribuição Aleatória , Schistosoma mansoni/efeitos dos fármacosAssuntos
Nitroquinolinas/uso terapêutico , Oxamniquine/uso terapêutico , Praziquantel/uso terapêutico , Esquistossomose mansoni/tratamento farmacológico , Adolescente , Adulto , Criança , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Contagem de Ovos de Parasitas , Distribuição AleatóriaRESUMO
In 10 patients with neurocysticercosis (NC), an assessment was made of the praziquantel (PZQ) concentration in the cerebrospinal fluid (CSF), in non-deproteinized serum and in protein-free serum: before administration of the drug and the 1st., 7th. and 21st. days of oral administration (50mg/kg/day during 21 days). Samples of CSF and blood were collected three hours after the last administration of the daily total dosage, on the 1st. and 21st. days; and from 2 to 6 hours after drug administration on the 7th. day. The total daily dosage was distributed into three equal parts of 1/3 each, with a 4 hours' interval between intakes, except in the last 5 cases, who on the 21st. day only were given the total daily dosage on a single administration. Results have shown dispersion in serum concentrations, which are similar to those seen in normal subjects as recorded in literature. There is a correlation between PZQ levels in the CSF and in the serum, the latter being very close to those found in protein-free serum fraction. The statistical treatment of results allowed the following considerations: PZQ concentrations in the CSF and in the protein free serum are in balance from the pharmacodynamic standpoint on the first day; this balance is maintained up to the 21st. day although at different levels from those seen on the 7th. day; on the 21st. day PZQ contents in CSF goes back to its similar values as recorded on the 1st. day, and this suggests that the participation of drug interaction factors has been reduced to non-significant levels. However, several factors can influence PZQ concentration in CSF, as absorption rate, liver first-pass effect and blood-brain barrier changes, and individual dose should be established for each patient based on drug concentration monitoring in the serum and/or in the CSF.